8-K: Cabaletta Bio Accelerates Autoimmune CAR T Program

Cabaletta Bio announces significant clinical progress and FDA alignment for its rese-cel CAR T therapy across multiple autoimmune diseases, targeting a 2027 BLA submission for Myositis.

Summary

• FDA alignment has been achieved for the Myositis registrational cohort, a single-arm study of 14 Dermatomyositis (DM)/Antisynthetase Syndrome (ASyS) patients within the RESET-Myositis trial, with primary endpoint of moderate or major TIS response at 16 weeks off immunomodulators and on no or low dose steroids.
• All DM/ASyS patients with 16 weeks follow-up who met inclusion criteria in the Phase 1/2 trial achieved the registrational primary endpoint.
• Myositis Biologics License Application (BLA) submission is on track for 2027, with the registrational cohort initiating in 4Q25.
• FDA alignment on registrational design is anticipated for Systemic Lupus Erythematosus (SLE)/Lupus Nephritis (LN) and Systemic Sclerosis (SSc) in 4Q25, and for Myasthenia Gravis (MG) in 1H26.
• Enrollment is complete in Phase 1/2 trials for SLE/LN, SSc, and MG.
• In SSc, all patients with 3 months follow-up achieved an rCRISS-25 response off all immunomodulators and steroids.
• In Lupus, 3 out of 4 SLE patients with 3 months follow-up achieved DORIS (Definition of Remission in SLE), with the fourth achieving Complete Renal Response (CRR); 3 out of 4 LN patients achieved renal response.
• Rese-cel without preconditioning (PC) showed early near-complete symptom resolution in 2 out of 3 Pemphigus Vulgaris (PV) patients in the initial dose cohort.
• The safety profile in the first 32 patients dosed with preconditioning supports potential outpatient administration, with 94% experiencing no Cytokine Release Syndrome (CRS) or Grade 1 CRS, and 94% experiencing no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
• Plans are accelerating to initiate a no preconditioning cohort in the RESET-SLE trial, with initial clinical data expected in 2026.
• Advancement of a whole blood manufacturing program aims to eliminate the burden of apheresis, and an expanded partnership for automated manufacturing with Cellares has been completed.
• Commercial supply strategy is in hand, with process qualification and validation activities planned for BLA submission, including lentiviral vector process at Oxford and drug product process at Lonza.

Sentiment

Score: 9

Explanation: The filing presents exceptionally strong clinical data across multiple autoimmune indications, coupled with significant FDA alignment on registrational pathways. The safety profile appears manageable, and manufacturing advancements are underway. This indicates robust progress and a clear path towards commercialization for a potentially transformative therapy in areas of high unmet need.

Positives

• Achieved FDA alignment on registrational cohort design for Myositis, providing a clear and accelerated path to BLA submission by 2027.
• Demonstrated transformative clinical responses in the majority of rese-cel patients across Myositis, SLE/LN, and SSc, with patients discontinuing immunomodulators.
• Reported a favorable safety profile for rese-cel, with low rates of high-grade CRS and ICANS, supporting potential outpatient administration.
• Successfully completed enrollment in Phase 1/2 trials for SLE/LN, SSc, and MG, indicating strong operational execution.
• Initiating a no preconditioning cohort in RESET-SLE and showing promising early data in Pemphigus Vulgaris without preconditioning, potentially broadening patient access and reducing treatment burden.
• Advancing manufacturing capabilities with a whole blood program and automated processes, which could enhance scalability and efficiency for commercial supply.

Negatives

• One ASyS patient (ASyS-2) showed only a minimal TIS response at Week 16, with Jo-1 antibody levels trending up, suggesting potential limitations in response durability for some patients.
• While generally well-tolerated, some patients in lupus and SSc trials experienced Grade 3 or 4 related serious adverse events, including ICANS, pancytopenia, hypercapnic respiratory failure, and encephalopathy, although these were transient.
• The disclaimer highlights risks related to the ability to fund operations and continue as a going concern, which is a common but notable concern for development-stage biopharmaceutical companies.

Risks

• Success, cost, and timing of development activities and clinical trials.
• Ability to demonstrate sufficient evidence of safety, efficacy, and tolerability in clinical trials.
• Risk that results observed with similarly-designed constructs are not indicative of results with rese-cel.
• Risk that signs of biologic activity or persistence may not inform long-term results.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Risk that modifications to trial design or approach may not have the intended benefits or may require further modification.
• Ability to protect and maintain intellectual property position.
• Risks related to relationships with third parties.
• Uncertainties related to regulatory agencies' evaluation of regulatory filings and other information.
• Ability to retain and recognize the intended incentives conferred by any regulatory designations.
• Risks related to regulatory filings and potential clearance.
• Risk that any one or more product candidates will not be successfully developed and commercialized.
• Risk that results of preclinical or clinical studies will not be predictive of future results.
• Risks related to volatile market and economic conditions.
• Ability to fund operations and continue as a going concern.

Future Outlook

Cabaletta Bio anticipates initiating the Myositis registrational cohort in 4Q25, with a BLA submission targeted for 2027. FDA alignment on registrational designs for SLE/LN and SSc is expected in 4Q25, and for MG in 1H26. The company plans to accelerate the initiation of a no preconditioning cohort in the RESET-SLE trial, with initial clinical data anticipated in 2026. Further clinical data for additional indications and RESET-PV are expected in 2H26, alongside progress on commercial supply readiness and Cellares automated process data. The company aims to leverage its experience to accelerate its pipeline to approval and launch, developing transformative therapies for patients.

Management Comments

• Our mission is to develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases.

Industry Context

The announcement positions Cabaletta Bio at the forefront of developing targeted cellular therapies for autoimmune diseases, an area with significant unmet medical needs. Many of these conditions, such as Myositis, SLE, SSc, and MG, are chronic, debilitating, and often refractory to existing treatments, which typically involve broad immunosuppression with considerable side effects. Rese-cel, a CD19-CAR T therapy, offers the potential for a 'drug-free, durable transformative clinical response' through an immune reset, a paradigm shift from current symptomatic or broadly immunosuppressive therapies like IVIg, methotrexate, or rituximab. The expansion into no-preconditioning regimens could further enhance the competitive profile by reducing treatment burden and expanding accessibility, potentially setting a new standard in autoimmune disease management.

Comparison to Industry Standards

• Rese-cel's approach of CD19-CAR T cell therapy for autoimmune diseases is a novel and potentially transformative strategy, moving beyond traditional immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate) and biologics (e.g., rituximab, tocilizumab, eculizumab) which often provide transient effects and carry long-term side effects.
• The observed complete and transient B cell depletion, followed by B cell repopulation, is consistent with the mechanism of action seen in oncology CAR T therapies and academic studies in autoimmune disease, suggesting a deeper and more sustained immune reset than monoclonal antibodies.
• The safety profile, with 94% of patients experiencing no or Grade 1 CRS and 94% no ICANS with preconditioning, compares favorably to the initial safety profiles of approved oncology CAR T products, which often have higher rates of these adverse events.
• The exploration of rese-cel without preconditioning, showing similar pharmacokinetics and B cell depletion, could differentiate it significantly from other CAR T therapies by reducing the intensity and complexity of the treatment regimen, potentially enabling outpatient administration and broader adoption, similar to how less intensive regimens are sought in other cell therapies.
• The FDA alignment on registrational trial designs for multiple indications, including a 14-patient single-arm cohort for Myositis, indicates a potentially accelerated regulatory pathway, which is a significant advantage compared to the lengthy and complex development typical for new autoimmune therapies.

Stakeholder Impact

• **Shareholders:** Significant positive impact due to strong clinical data, FDA alignment, and accelerated regulatory pathways, indicating potential for substantial future value creation and market penetration in large, underserved autoimmune markets.
• **Patients:** Highly positive impact with the potential for transformative, drug-free, and durable clinical responses for severe, refractory autoimmune diseases, offering hope beyond current symptomatic treatments.
• **Employees:** Positive impact from the company's strong progress and clear strategic direction, fostering a sense of purpose and stability in advancing novel therapies.
• **Regulatory Authorities:** Continued engagement with the FDA through Type C meetings and alignment on registrational trial designs demonstrates a collaborative and transparent approach to drug development.

Next Steps

• Initiate enrollment in the Myositis registrational cohort in 4Q25.
• Present complete Phase 1/2 data for Myositis, Lupus, SSc, and MG in 2H25.
• Align with FDA on registrational cohort designs for Lupus, SSc, and MG in 4Q25 and 1H26.
• Initiate enrollment in registrational cohorts for Lupus, SSc, and MG in 1H26.
• Initiate a no preconditioning cohort in the RESET-SLE trial, with initial clinical data expected in 2026.
• Advance commercial supply readiness and innovation, including process qualification and validation activities for BLA submission.
• Obtain initial clinical data from Cellares automated process in 2H26.
• Submit BLA for Myositis in 2027.

Key Dates

Recommendation

The filing provides compelling evidence of Cabaletta Bio's strong progress with rese-cel, a potentially curative CAR T therapy for multiple autoimmune diseases. The FDA alignment on registrational trial designs for Myositis, with a BLA submission targeted for 2027, significantly de-risks the program and provides a clear path to market. Efficacy data across Myositis, SLE/LN, and SSc are highly positive, showing transformative clinical responses and the ability for patients to discontinue immunomodulators. The manageable safety profile and the strategic move towards no-preconditioning regimens further enhance the commercial potential and patient accessibility. Given the high unmet medical need in these large markets and the innovative nature of the therapy, these updates position Cabaletta Bio for substantial long-term growth and make it a strong investment opportunity.

Keywords

Cabaletta Bio, rese-cel, CABA-201, CAR T therapy, autoimmune disease, Myositis, Dermatomyositis, Antisynthetase Syndrome, Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Pemphigus Vulgaris, clinical trials, FDA alignment, BLA submission, cell therapy, CD19-CAR T, RESET program